Actualités Bristol Myers Squibb Co - BMY | Actions New York Stock Exchange

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy...

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

-- Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs...

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday...

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given over three- to...

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

POETYK PsA-1 and POETYK PsA-2 trials met primary endpoint, with significantly greater proportion of Sotyktu-treated patients achieving ACR20...

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Approval based on results of the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo plus Yervoy demonstrated...

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2024 on Thursday, February 6, 2025. Company executives will...

Bristol Myers Squibb Announces Dividend Increase

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per...

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Data presentations highlight BMS’ leadership and commitment to harnessing the full potential of cell therapy, with advances in blood cancers and...

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2024 Global Healthcare Conference. Christopher...

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Data from more than 20 programs, including new research from cell therapy and targeted protein degradation platforms, showcase the depth and...

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated...

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Recommendation based on data from registrational TRIDENT-1 and CARE trials, which demonstrated robust responses and durable activity with...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody...

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bristol Myers Squibb Co (BMY)

Outils de qualité professionnelle, pour des investisseurs individuels.

BMY Actualités

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Bristol Myers Squibb Announces Dividend Increase

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bristol Myers Squibb Co (BMY) Actualités

Bristol Myers Squibb Co (BMY)

Outils de qualité professionnelle, pour des investisseurs individuels.

BMY Actualités

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Bristol Myers Squibb Announces Dividend Increase

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités